ArticleOncology letters2026
Prognosis of liver transplantation and hepatectomy in patients with hepatocellular carcinoma meeting the Milan criteria: A systematic review and meta-analysis.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation (LT) and liver resection (LR) are two curative treatment options for patients with hepatocellular carcinoma (HCC) meeting the Milan criteria. However, the optimal choice between LT and LR remains contentious. The present meta-analysis aimed to provide additional evidence to optimize treatment decisions for patients with HCC. A comprehensive literature search was conducted across multiple databases, including PubMed, Embase, Cochrane, Web of Science (Medline), OVID, Scopus, China National Knowledge Infrastructure, Value-Added Information Provider, Wanfang and China Biology Medicine, focusing on studies reporting on the prognosis of LR and LT in patients with HCC. The data were analyzed using Review Manager 5.4 software. Random-effects models were employed to compare the 1-, 3-, 5- and 10-year overall survival (OS) rates, disease-free survival (DFS) rates and recurrence rate (RR) between patients who underwent LT and those who underwent LR. In total, 36 studies encompassing 6,839 patients (3,894 in the LR group and 2,945 in the LT group) were included. The analysis revealed no significant difference in 1-year OS rate between the two groups. However, the LT group demonstrated significantly improved OS rates at 3, 5 and 10 years. Additionally, the LT group indicated significantly improved DFS rates at all time points (1, 3, 5 and 10 years) compared with the LR group. Postoperative RR was significantly lower in the LT group compared with that in the LR group. In conclusion, in patients with HCC meeting the Milan criteria, LT provides improvements in OS and DFS rates, and results in a lower RR compared with LR. Therefore, LT should be considered the preferred treatment option for these patients within the Milan criteria if donor organs are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.